Microglial ion channels as potential targets for neuroprotection in Parkinson's disease

Neural Plasticity

Volumn 2013, Issue , 2013, Pages

  Richardson, Jason R ^a   Hossain, Muhammad M ^a  

^a RUTGERS ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; 2 [4 (2,5 DIFLUOROBENZYLOXY)PHENOXY] 5 ETHOXYANILINE; 3 NITROTYROSINE; 7 NITROINDAZOLE; ALPHA SYNUCLEIN; ALPHA TOCOPHEROL; APOCYNIN; CALCIUM CHANNEL; CALPAIN; DEXTROMETHORPHAN; DIPHENYLIODONIUM SALT; GLYCERYL TRINITRATE; IBUPROFEN; INDUCIBLE NITRIC OXIDE SYNTHASE; ION CHANNEL; ISRADIPINE; MINOCYCLINE; NEUROMELANIN; NIFEDIPINE; NIMODIPINE; NITRIC OXIDE; PARAQUAT; POTASSIUM CHANNEL; PROTON CHANNEL HV1; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; SODIUM CALCIUM EXCHANGE PROTEIN; SODIUM CHANNEL; TRANSIENT RECEPTOR POTENTIAL CHANNEL; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; ANTIPARKINSON AGENT; ION; NEUROPROTECTIVE AGENT;

ARTICLE; BLOOD BRAIN BARRIER; CELL ACTIVATION; CLINICAL TRIAL (TOPIC); CYTOKINE PRODUCTION; DISEASE COURSE; DOPAMINERGIC NERVE CELL; DRUG EFFICACY; DRUG PENETRATION; DRUG TARGETING; DRUG WITHDRAWAL; GENE DELETION; HOMEOSTASIS; HUMAN; LIVER TOXICITY; MICROGLIA; NERVE CELL NECROSIS; NERVE DEGENERATION; NERVE FIBER DEGENERATION; NERVOUS SYSTEM INFLAMMATION; NEUROPATHOLOGY; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; PARKINSON DISEASE; PATHOPHYSIOLOGY; RETINA GANGLION CELL; SHY DRAGER SYNDROME; ANIMAL; DRUG EFFECT; INFLAMMATION; MACROPHAGE ACTIVATION; METABOLISM; PATHOLOGY; PHYSIOLOGY; REVIEW;

ANIMALS; ANTIPARKINSON AGENTS; HOMEOSTASIS; HUMANS; INFLAMMATION; ION CHANNELS; IONS; MACROPHAGE ACTIVATION; MICROGLIA; NEUROPROTECTIVE AGENTS; PARKINSON DISEASE;

EID: 84889071254     PISSN: 20905904     EISSN: 16875443     Source Type: Journal    
DOI: 10.1155/2013/587418     Document Type: Article

References (77)

1. Dorsey E. R., Constantinescu R., Thompson J. P., Biglan K. M., Holloway R. G., Kieburtz K., Marshall F. J., Ravina B. M., Schifitto G., Siderowf A., Tanner C. M., Projected number of people with Parkinson disease in the most populous nations, 2005 through 2030. Neurology 2007 68 5 384 386 2-s2.0-33846572874 10.1212/01.wnl.0000247740.47667.03 (Pubitemid 46184217)
2. Bennett J. P., Free radicals, oxidative stress and the origin of Parkinson's disease. Journal of the Neurological Sciences 1999 170 2 75 76 2-s2.0-0032748299 10.1016/S0022-510X(99)00191-4 (Pubitemid 29528528)
3. Lawson L. J., Perry V. H., Dri P., Gordon S., Heterogeneity in the distribution and morphology of microglia in the normal adult mouse brain. Neuroscience 1990 39 1 151 170 2-s2.0-0025220976 10.1016/0306-4522(90)90229-W
4. Dexter D. T., Sian J., Rose S., Hindmarsh J. G., Mann V. M., Cooper J. M., Wells F. R., Daniel S. E., Lees A. J., Schapira A. H. V., Jenner P., Marsden C. D., Indices of oxidative stress and mitochondrial function in individuals with incidental Lewy body disease. Annals of Neurology 1994 35 1 38 44 2-s2.0-0028091176 (Pubitemid 24027604)
5. Jenner P., Olanow C. W., Oxidative stress and the pathogenesis of Parkinson's disease. Neurology 1996 47 6, supplement 3 S161 S170 2-s2.0-0029751104 (Pubitemid 26422582)
6. McGeer P. L., Itagaki S., Boyes B. E., McGeer E. G., Reactive microglia are positive for HLA-DR in the substantia nigra of Parkinson's and Alzheimer's disease brains. Neurology 1988 38 8 1285 1291 2-s2.0-0023789193
7. Langston J. W., Forno L. S., Tetrud J., Reeves A. G., Kaplan J. A., Karluk D., Evidence of active nerve cell degeneration in the substantia nigra of humans years after 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine exposure. Annals of Neurology 1999 46 4 598 605 (Pubitemid 29466438)
8. Sherer T. B., Betarbet R., Kim J.-H., Greenamyre J. T., Selective microglial activation in the rat rotenone model of Parkinson's disease. Neuroscience Letters 2003 341 2 87 90 2-s2.0-0037402801 10.1016/S0304-3940(03) 00172-1 (Pubitemid 36398476)
9. Hamill C. E., Caudle W. M., Richardson J. R., Yuan H., Pennell K. D., Greene J. G., Miller G. W., Traynelis S. F., Exacerbation of dopaminergic terminal damage in a mouse model of Parkinson's disease by the G-protein-coupled receptor protease-activated receptor 1. Molecular Pharmacology 2007 72 3 653 664 2-s2.0-34548360527 10.1124/mol.107.038158 (Pubitemid 47347300)
10. Purisai M. G., McCormack A. L., Cumine S., Li J., Isla M. Z., di Monte D. A., Microglial activation as a priming event leading to paraquat-induced dopaminergic cell degeneration. Neurobiology of Disease 2007 25 2 392 400 2-s2.0-33846308531 10.1016/j.nbd.2006.10.008 (Pubitemid 46124019)
11. McGeer P. L., Schwab C., Parent A., Doudet D., Presence of reactive microglia in monkey substantia nigra years after 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine administration. Annals of Neurology 2003 54 5 599 604 2-s2.0-0242384667 10.1002/ana.10728 (Pubitemid 37346066)
12. Gerhard A., Pavese N., Hotton G., Turkheimer F., Es M., Hammers A., Eggert K., Oertel W., Banati R. B., Brooks D. J., In vivo imaging of microglial activation with [11C](R)-PK11195 PET in idiopathic Parkinson's disease. Neurobiology of Disease 2006 21 2 404 412 2-s2.0-30744472146 10.1016/j.nbd.2005.08.002 (Pubitemid 43099863)
13. LeWitt P. A., Clinical trials of neuroprotection in Parkinson's disease: long-term selegiline and alpha-tocopherol treatment. Journal of Neural Transmission, Supplement 1994 43 171 181 2-s2.0-0028170916
14. Chen H., Zhang S. M., Hernán M. A., Schwarzschild M. A., Willett W. C., Colditz G. A., Speizer F. E., Ascherio A., Nonsteroidal anti-inflammatory drugs and the risk of Parkinson disease. Archives of Neurology 2003 60 8 1059 1064 2-s2.0-0041653249 10.1001/archneur.60.8.1059 (Pubitemid 36975791)
15. Ton T. G., Heckbert S. R., Longstreth W. T. Jr., Rossing M. A., Kukull W. A., Franklin G. M., Swanson P. D., Smith-Weller T., Checkoway H., Nonsteroidal anti-inflammatory drugs and risk of Parkinson's disease. Movement Disorders 2006 21 7 964 969 2-s2.0-33746894717 10.1002/mds.20856 (Pubitemid 44184597)
16. Gao X., Chen H., Schwarzschild M. A., Ascherio A., Use of ibuprofen and risk of Parkinson disease. Neurology 2011 76 10 863 869 2-s2.0-79952941281 10.1212/WNL.0b013e31820f2d79
17. Seidl S. E., Potashkin J. A., The promise of neuroprotective agents in Parkinson's disease. Frontiers in Neurology 2011 2 68
18. Wu D. C., Jackson-Lewis V., Vila M., Tieu K., Teismann P., Vadseth C., Choi D.-K., Ischiropoulos H., Przedborski S., Blockade of microglial activation is neuroprotective in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson disease. Journal of Neuroscience 2002 22 5 1763 1771 2-s2.0-0036522967 (Pubitemid 35386294)
19. Yang L., Sugama S., Chirichigno J. W., Gregorio J., Lorenzl S., Shin D. H., Browne S. E., Shimizu Y., Joh T. H., Beal M. F., Albers D. S., Minocycline enhances MPTP toxicity to dopaminergic neurons. Journal of Neuroscience Research 2003 74 2 278 285 2-s2.0-0141593395 10.1002/jnr.10709 (Pubitemid 37193714)
20. Diguet E., Fernagut P.-O., Wei X., Du Y., Rouland R., Gross C., Bezard E., Tison F., Deleterious effects of minocycline in animal models of Parkinson's disease and Huntington's disease. European Journal of Neuroscience 2004 19 12 3266 3276 2-s2.0-3042755065 10.1111/j.0953-816X.2004.03372.x (Pubitemid 38859544)
21. Sriram K., Miller D. B., O'Callaghan J. P., Minocycline attenuates microglial activation but fails to mitigate striatal dopaminergic neurotoxicity: role of tumor necrosis factor- α Journal of Neurochemistry 2006 96 3 706 718 2-s2.0-33645123006 10.1111/j.1471-4159.2005.03566.x
22. Gordon P. H., Moore D. H., Miller R. G., Florence J. M., Verheijde J. L., Doorish C., Hilton J. F., Spitalny G. M., MacArthur R. B., Mitsumoto H., Neville H. E., Boylan K., Mozaffar T., Belsh J. M., Ravits J., Bedlack R. S., Graves M. C., McCluskey L. F., Barohn R. J., Tandan R., Efficacy of minocycline in patients with amyotrophic lateral sclerosis: a phase III randomised trial. Lancet Neurology 2007 6 12 1045 1053 2-s2.0-36148960127 10.1016/S1474-4422(07) 70270-3 (Pubitemid 350116691)
23. Dodel R., Spottke A., Gerhard A., Reuss A., Reinecker S., Schimke N., Trenkwalder C., Sixel-Döring F., Herting B., Kamm C., Gasser T., Sawires M., Geser F., Köllensperger M., Seppi K., Kloss M., Krause M., Daniels C., Deuschl G., Böttger S., Naumann M., Lipp A., Gruber D., Kupsch A., Du Y., Turkheimer F., Brooks D. J., Klockgether T., Poewe W., Wenning G., Schade-Brittinger C., Oertel W. H., Eggert K., Minocycline 1-year therapy in multiple-system-atrophy: effect on clinical symptoms and [11C] (R)-PK11195 PET (MEMSA-trial). Movement Disorders 2010 25 1 97 107 2-s2.0-75749146196 10.1002/mds.22732
24. Block M. L., Zecca L., Hong J.-S., Microglia-mediated neurotoxicity: uncovering the molecular mechanisms. Nature Reviews Neuroscience 2007 8 1 57 69 2-s2.0-33845768784 10.1038/nrn2038 (Pubitemid 46011999)
25. Dutta G., Zhang P., Liu B., The lipopolysaccharide Parkinson's disease animal model: mechanistic studies and drug discovery. Fundamental and Clinical Pharmacology 2008 22 5 453 464 2-s2.0-52449115580 10.1111/j.1472-8206.2008. 00616.x
26. Levesque S., Wilson B., Gregoria V., Thorpe L. B., Dallas S., Polikov V. S., Hong J.-S., Block M. L., Reactive microgliosis: extracellular-calpain and microglia-mediated dopaminergic neurotoxicity. Brain 2010 133 3 808 821 2-s2.0-77950251171 10.1093/brain/awp333
27. Wilms H., Rosenstiel P., Sievers J., Deuschl G., Zecca L., Lucius R., Activation of microglia by human neuromelanin is NF-kappaB dependent and involves p38 mitogen-activated protein kinase: implications for Parkinson's disease. The FASEB Journal 2003 17 3 500 502 2-s2.0-0037366093
28. Good P. F., Hsu A., Werner P., Perl D. P., Olanow C. W., Protein nitration in Parkinson's disease. Journal of Neuropathology and Experimental Neurology 1998 57 4 338 342 2-s2.0-0031939204 (Pubitemid 28182632)
29. Liberatore G. T., Jackson-Lewis V., Vukosavic S., Mandir A. S., Vila M., Mcauliffe W. G., Dawson V. L., Dawson T. M., Przedborski S., Inducible nitric oxide synthase stimulates dopaminergic neurodegeneration in the MPTP model of Parkinson disease. Nature Medicine 1999 5 12 1403 1409 2-s2.0-0032710609 10.1038/70978
30. Hirsch E. C., Hunot S., Neuroinflammation in Parkinson's disease: a target for neuroprotection? The Lancet Neurology 2009 8 4 382 397 2-s2.0-62549133546 10.1016/S1474-4422(09)70062-6
31. Sriram K., Matheson J. M., Benkovic S. A., Miller D. B., Luster M. I., O'Callaghan J. P., Mice deficient in TNF receptors are protected against dopaminergic neurotoxicity: implications for Parkinson's disease. The FASEB Journal 2002 16 11 1474 1476 2-s2.0-0036719568
32. Kraft A. D., McPherson C. A., Harry G. J., Heterogeneity of microglia and TNF signaling as determinants for neuronal death or survival. NeuroToxicology 2009 30 5 785 793 2-s2.0-70349832717 10.1016/j.neuro.2009.07.001
33. Qin L., Liu Y., Wang T., Wei S.-J., Block M. L., Wilson B., Liu B., Hong J.-S., NADPH oxidase mediates lipopolysaccharide-induced neurotoxicity and proinflammatory gene expression in activated microglia. Journal of Biological Chemistry 2004 279 2 1415 1421 2-s2.0-0346463000 10.1074/jbc.M307657200 (Pubitemid 38082669)
34. Surace M. J., Block M. L., Targeting microglia-mediated neurotoxicity: the potential of NOX2 inhibitors. Cellular and Molecular Life Sciences 2012 69 14 2409 2427 10.1007/s00018-012-1015-4
35. Babior B. M., The NADPH oxidase of endothelial cells. IUBMB Life 2000 50 4-5 267 269 2-s2.0-0034458228 10.1080/15216540051080976 (Pubitemid 32289084)
36. Görlach A., Brandes R. P., Nguyen K., Amidi M., Dehghani F., Busse R., A gp91phox containing NADPH oxidase selectively expressed in endothelial cells is a major source of oxygen radical generation in the arterial wall. Circulation Research 2000 87 1 26 32 2-s2.0-0034617071 (Pubitemid 30456931)
37. Ushio-Fukai M., Tang Y., Fukai T., Dikalov S. I., Ma Y., Fujimoto M., Quinn M. T., Pagano P. J., Johnson C., Alexander R. W., Novel role of gp91phox-containing NAD(P)H oxidase in vascular endothelial growth factor-induced signaling and angiogenesis. Circulation Research 2002 91 12 1160 1167 2-s2.0-0036954803 10.1161/01.RES.0000046227.65158.F8 (Pubitemid 36076365)
38. Qin L., Crews F. T., NADPH oxidase and reactive oxygen species contribute to alcohol-induced microglial activation and neurodegeneration. Journal of Neuroinflammation 2012 9, article 5 2-s2.0-84855570853 10.1186/1742-2094-9-5
39. Sorce S., Krause K.-H., NOX enzymes in the central nervous system: from signaling to disease. Antioxidants and Redox Signaling 2009 11 10 2481 2504 2-s2.0-67651184281 10.1089/ars.2009.2578
40. Wu D.-C., Teismann P., Tieu K., Vila M., Jackson-Lewis V., Ischiropoulos H., Przedborski S., NADPH oxidase mediates oxidative stress in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of Parkinson's disease. Proceedings of the National Academy of Sciences of the United States of America 2003 100 10 6145 6150 2-s2.0-0037947448 10.1073/pnas.0937239100 (Pubitemid 36576945)
41. + exchanger isoform 1 is neuroprotective in neonatal hypoxic ischemic brain injury. Antioxidants and Redox Signaling 2011 14 10 1803 1813 2-s2.0-79954596665 10.1089/ars.2010.3468
42. Gao H.-M., Zhou H., Hong J.-S., NADPH oxidases: novel therapeutic targets for neurodegenerative diseases. Trends in Pharmacological Sciences 2012 33 6 295 303 2-s2.0-84859514311 10.1016/j.tips.2012.03.008
43. Black J. A., Liu S., Waxman S. G., Sodium channel activity modulates multiple functions in microglia. Glia 2009 57 10 1072 1081 2-s2.0-69449105146 10.1002/glia.20830
44. Eder C., Ion channels in microglia (brain macrophages). American Journal of Physiology-Cell Physiology 1998 275 2, part 1 C327 C342 2-s2.0-0031817079
45. Eder C., Regulation of microglial behavior by ion channel activity. Journal of Neuroscience Research 2005 81 3 314 321 2-s2.0-25444505872 10.1002/jnr.20476 (Pubitemid 41359285)
46. Schilling T., Eder C., Ion channel expression in resting and activated microglia of hippocampal slices from juvenile mice. Brain Research 2007 1186 1 21 28 2-s2.0-37649011460 10.1016/j.brainres.2007.10.027
47. Färber K., Kettenmann H., Physiology of microglial cells. Brain Research Reviews 2005 48 2 133 143 2-s2.0-17844396885 10.1016/j.brainresrev. 2004.12.003 (Pubitemid 40585744)
48. Färber K., Kettenmann H., Functional role of calcium signals for microglial function. Glia 2006 54 7 656 665 2-s2.0-33750305578 10.1002/glia.20412 (Pubitemid 44629629)
49. Kettenmann H., Hoppe D., Gottmann K., Banati R., Kreutzberg G., Cultured microglial cells have a distinct pattern of membrane channels different from peritoneal macrophages. Journal of Neuroscience Research 1990 26 3 278 287 2-s2.0-0025043211 10.1002/jnr.490260303 (Pubitemid 20264020)
50. + current and resultant neurotoxic activity. PLoS One 2013 8 5 e64904
51. Fordyce C. B., Jagasia R., Zhu X., Schlichter L. C., Microglia Kv1.3 channels contribute to their ability to kill neurons. Journal of Neuroscience 2005 25 31 7139 7149 2-s2.0-23444436221 10.1523/JNEUROSCI.1251-05.2005 (Pubitemid 41113930)
52. Skaper S. D., Ion channels on microglia: therapeutic targets for neuroprotection. CNS & Neurological Disorders Drug Targets 2011 10 1 44 56 2-s2.0-79960776760
53. + channel KCNN4/KCa3.1 contributes to microglia activation and nitric oxide-dependent neurodegeneration. Journal of Neuroscience 2007 27 1 234 244 2-s2.0-33846122620 10.1523/JNEUROSCI.3593-06.2007 (Pubitemid 46089977)
54. Dolga A. M., Culmsee C., Protective roles for potassium SK/KCa2 channels in microglia and neurons. Frontiers in Pharmacology 2012 3 196 10.3389/fphar.2012.00196
55. Ortega F. J., Gimeno-Bayon J., Espinosa-Parrilla J. F., Carrasco J. L., Batlle M., Pugliese M., Mahy N., Rodríguez M. J., ATP-dependent potassium channel blockade strengthens microglial neuroprotection after hypoxia-ischemia in rats. Experimental Neurology 2012 235 1 282 296 2-s2.0-84859922500 10.1016/j.expneurol.2012.02.010
56. 2+ channels. American Journal of Physiology-Cell Physiology 1994 266 6, part 1 C1650 C1655 2-s2.0-0028227123
57. Möller T., Calcium signaling in microglial cells. Glia 2002 40 2 184 194 2-s2.0-0036847845 10.1002/glia.10152 (Pubitemid 35337376)
58. Kang S., Cooper G., Dunne S. F., Dusel B., Luan C. H., Surmeier D. J., Silverman R. B., CaV1.3-selective L-type calcium channel antagonists as potential new therapeutics for Parkinson's disease. Nature Communications 2012 3 1146 10.1038/ncomms2149
59. Ilijic E., Guzman J. N., Surmeier D. J., The L-type channel antagonist isradipine is neuroprotective in a mouse model of Parkinson's disease. Neurobiology of Disease 2011 43 2 364 371 2-s2.0-79958204001 10.1016/j.nbd.2011.04.007
60. Li Y., Hu X., Liu Y., Bao Y., An L., Nimodipine protects dopaminergic neurons against inflammation-mediated degeneration through inhibition of microglial activation. Neuropharmacology 2009 56 3 580 589 2-s2.0-58749084091 10.1016/j.neuropharm.2008.10.016
61. 2+ entry in rat microglia. Channels 2009 3 2 129 139 2-s2.0-67049156216
62. Ho K. W., Ward N. J., Calkins D. J., TRPV1: a stress response protein in the central nervous system. American Journal of Neurodegenerative Disease 2012 1 1 1 14
63. Black J. A., Waxman S. G., Sodium channels and microglial function. Experimental Neurology 2012 234 2 302 315 2-s2.0-84858158701 10.1016/j.expneurol.2011.09.030
64. Hossain M. M., Sonsalla P. K., Richardson J. R., Coordinated role of voltage-gated sodium channels and the Na/H exchanger in sustaining microglial activation during inflammation. Toxicology and Applied Pharmacology 2013 10.1016/j.taap.2013.09.011
65. Craner M. J., Damarjian T. G., Liu S., Hains B. C., Lo A. C., Black J. A., Newcombe J., Cuzner M. L., Waxman S. G., Sodium channels contribute to microglia/macrophage activation and function in EAE and MS. Glia 2005 49 2 220 229 2-s2.0-13244258365 10.1002/glia.20112 (Pubitemid 40188501)
66. Black J. A., Liu S., Carrithers M., Carrithers L. M., Waxman S. G., Exacerbation of experimental autoimmune encephalomyelitis after withdrawal of phenytoin and carbamazepine. Annals of Neurology 2007 62 1 21 33 2-s2.0-34547773583 10.1002/ana.21172 (Pubitemid 47235277)
67. + exchanger. Canadian Journal of Physiology and Pharmacology 2006 84 11 1081 1095 2-s2.0-33947531619 10.1139/Y06-065 (Pubitemid 46465921)
68. + homeostasis. Journal of Neuroscience 2010 30 45 15210 15220 2-s2.0-78149481646 10.1523/JNEUROSCI.3950-10.2010
69. Scholz W., Albus U., Counillon L., Gögelein H., Lang H.-J., Linz W., Weichert A., Schölkens B. A., Protective effects of HOE642, a selective sodium-hydrogen exchange subtype 1 inhibitor, on cardiac ischaemia and reperfusion. Cardiovascular Research 1995 29 2 260 268 2-s2.0-0028851256 10.1016/0008-6363(96)88579-8
70. + exchanger isoform 1-null mice after in vitro and in vivo ischemia. Journal of Neuroscience 2005 25 49 11256 11268 2-s2.0-30544436513 10.1523/JNEUROSCI.3271-05.2005 (Pubitemid 43083700)
71. Shi Y., Chanana V., Watters J. J., Ferrazzano P., Sun D., Role of sodium/hydrogen exchanger isoform 1 in microglial activation and proinflammatory responses in ischemic brains. Journal of Neurochemistry 2011 119 1 124 135 2-s2.0-80052647286 10.1111/j.1471-4159.2011.07403.x
72. 2+ overload. Journal of Neuroscience Research 2012 90 4 860 869 2-s2.0-84856756086 10.1002/jnr.22818
73. Karmazyn M., NHE-1: still a viable therapeutic target. Journal of Molecular and Cellular Cardiology 2013 61 77 82
74. 2+ exchange inhibitor, prevents dopaminergic neurotoxicity in an MPTP mouse model of Parkinson's disease. Neuropharmacology 2011 61 8 1441 1451 2-s2.0-80053612497 10.1016/j.neuropharm.2011.08.041
75. Ramsey I. S., Moran M. M., Chong J. A., Clapham D. E., A voltage-gated proton-selective channel lacking the pore domain. Nature 2006 440 7088 1213 1216 2-s2.0-33646358260 10.1038/nature04700
76. Ramsey I. S., Ruchti E., Kaczmarek J. S., Clapham D. E., Hv1 proton channels are required for high-level NADPH oxidase-dependent superoxide production during the phagocyte respiratory burst. Proceedings of the National Academy of Sciences of the United States of America 2009 106 18 7642 7647 2-s2.0-66149104077 10.1073/pnas.0902761106
77. Wu L.-J., Wu G., Akhavan Sharif M. R., Baker A., Jia Y., Fahey F. H., Luo H. R., Feener E. P., Clapham D. E., The voltage-gated proton channel Hv1 enhances brain damage from ischemic stroke. Nature Neuroscience 2012 15 4 565 573 2-s2.0-84859209983 10.1038/nn.3059